We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App





Mesa Biotech Showcases PCR Testing Platform at Clinical Expo

By LabMedica International staff writers
Posted on 02 Aug 2018
Print article
Image: The Accula Dock system (Photo courtesy of Mesa Biotech).
Image: The Accula Dock system (Photo courtesy of Mesa Biotech).
Mesa Biotech Inc. (San Diego, CA, USA), a privately-held, molecular diagnostic company, showcased its affordable PCR (polymerase chain reaction) testing platform designed specifically for point-of-care (POC) infectious disease diagnosis at the 70th Annual American Association of Clinical Chemistry Scientific Meeting & Clinical Lab Expo (AACC). AACC 2018 was held on July 29 – August 2, 2018, in Chicago, Illinois, USA.

Mesa Biotech designs, develops, manufactures and commercializes next generation molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the POC. At AACC 2018, Mesa Biotech showcased its novel Accula System – a palm-sized, reusable dock with disposable test cassettes that offers the simplicity, convenience and procedural familiarity of traditional POC rapid immunoassays, while providing the superior sensitivity, specificity and information content of laboratory-based PCR testing. Test results are available in approximately 30 minutes to guide same-day treatment decisions. The handheld platform delivers flexibility in POC, ranging from the physician's office and walk-in clinics to emergency rooms. Accula Flu A/Flu B, the first commercialized test on the platform, is indicated for use with nasal swab collection that is less invasive than nasopharyngeal swabs and allows for a more comfortable specimen collection experience for the patient.

"We are excited to be a part of this leading industry conference and showcase our recently launched testing platform to the more than 20,000 attendees," said Hong Cai, Co-founder and Chief Executive Officer, Mesa Biotech, Inc. "AACC is an important opportunity for us to connect with global leaders, highlight new assays under development and identify additional partnership opportunities."

Related Links:
Mesa Biotech

Gold Supplier
Automated, Random Access Chemistry Analyzer
LIDA 300
New
Myoglobin Assay
Myoglobin Assay
New
Microtome
M-250
New
Albumin Urine Test
Micro-Albumin ELISA

Print article
SUGENTECH INC.

Channels

Clinical Chem.

view channel
Image: ELISA kit for liver-type fatty acid–binding protein (L-FABP). The level of L-FABP present in urine reflects the level of renal tubular dysfunction (Photo courtesy of Sekisui Medical Co)

Urinary Biomarkers Predict Weaning From Acute Dialysis Therapy

Acute kidney injury is associated with a higher risk of chronic kidney disease (CKD), end-stage renal disease, and long-term adverse cardiovascular effects. Critically ill patients with acute kidney injury... Read more

Microbiology

view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more

Pathology

view channel
Image: Breast cancer spread uncovered by new molecular microscopy (Photo courtesy of Wellcome Sanger Institute)

New Molecular Microscopy Tool Uncovers Breast Cancer Spread

Breast cancer commonly starts when cells start to grow uncontrollably, often due to mutations in the cells. Overtime the tumor becomes a patchwork of cells, called cancer clones, each with different mutations.... Read more

Industry

view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.